The third Wednesday of November each year is designated as "World COPD Day", which began in 2002 and was initiated by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), aiming to raise public awareness of Chronic Obstructive Pulmonary Disease (COPD) and promote early diagnosis and treatment.
Chronic Obstructive Pulmonary Disease (COPD), also known as chronic obstructive bronchitis, is a progressive and irreversible airflow limitation disease. Symptoms of COPD include coughing, expectoration, dyspnea, acute exacerbations, chest tightness, and shortness of breath. The main risk factors for COPD include long-term smoking, occupational exposure to dust and chemical substances, and are closely related to various inflammatory factors. Statistics show that COPD has become the third leading cause of death worldwide, following ischemic heart disease and stroke, severely affecting the quality of life of patients and imposing a heavy economic burden on individuals, society, and families.
The pathogenesis of COPD is complex, involving chronic inflammation, oxidative stress, protease-antiprotease imbalance, cellular senescence, and abnormal repair mechanisms [1][2][3]. Inflammation plays a key role in the development of the disease. Current treatment methods include long-acting bronchodilators and anti-inflammatory drugs, but these methods do not halt disease progression or solve all problems. New therapeutic targets under development include modulators of inflammatory mediators, protease inhibitors, antioxidants, kinase inhibitors, PDE4 inhibitors, NF-κB inhibitors, senolytics, and antifibrotic agents [4].
In terms of treatment, significant progress has been made in the field of COPD in recent years, including monoclonal antibodies and small molecule drugs. These drugs target key molecules such as IL-4Rα, PDE4, PDE3, TSLP, providing more treatment options for patients. For example, Stapokibart, a monoclonal antibody targeting IL-4Rα, was approved in China on July 30, 2024. Ensifentrine, a dual inhibitor of PDE3 and PDE4, was approved in the United States on March 10, 2023. Tezepelumab, a TSLP inhibitor, was approved in the United States on January 30, 2022. The launch of these new drugs not only enriches the treatment options for COPD but also brings more hope and personalized treatment plans for patients.
CUSABIO has long been committed to providing researchers with high-quality proteins, antibodies, ELISA kits, and other tool-based research reagent products. We have compiled a list of popular targets and related reagent products related to chronic obstructive pulmonary disease research for your selection.
Popular Research Targets:
● Recombinant Proteins Relevant to Chronic Obstructive Pulmonary Disease Research
Measured by its binding ability in a functional ELISA. Immobilized human C5AR1 at 10 μg/ml can bind Anti-C5AR1 recombinant antibody (CSB-RA003996A0HU), the EC50 is 1.239-3.760 ng/mL
Measured by its binding ability in a functional ELISA. Immobilized Human IL4 (CSB-MP011659HU) at 2μg/mL can bind biotinylated Human IL4R，the EC50 is 12.68-14.23 ng/mL.
Human TNFSF13B protein Fc tag (CSB-MP897523HU1) captured on COOH chip can bind Human BCMA protein Fc tag (CSB-MP023974HU1) with an affinity constant of 39 nM as detected by LSPR Assay.
-AC1.jpg)
Loaded Cynomolgus TSLP (R127A, R130S) on 96-Flat plate, can bind anti-TSLP antibody (CSB-RA025141MA1HU), with an affinity constant of 4.41 nM as determined in BLI assay (Gator Prime)
